Form 8-K - Current report:
SEC Accession No. 0000950170-25-083799
Filing Date
2025-06-09
Accepted
2025-06-09 16:33:09
Documents
11
Period of Report
2025-06-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crsp-20250605.htm   iXBRL 8-K 246463
2 EX-3.1 crsp-ex3_1.htm EX-3.1 617087
  Complete submission text file 0000950170-25-083799.txt   1048072

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250605.xsd EX-101.SCH 26983
13 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250605_htm.xml XML 4682
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37923 | Film No.: 251034596
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)